Clinical Trials Logo
  1. Home
  2. Methamphetamine Use Disorder
  3. NCT04713124

A Telephone-delievered Intervention to Reduce Methamphetamine Use — R2C-M  

Methamphetamine Use Disorder Clinical Trial

Official title:
Ready2Change-Methamphetmine (R2C-M): A Randomised Controlled Trial of a Telephone-delivered Intervention to Reduce Methamphetamine Use

Clinical Trial Summary

Australia has one of the highest rates of methamphetamine use in the world; however, uptake of face-to-face psychological treatment remains extremely low due to numerous individual (e.g. stigma, shame) and structural (e.g. service availability, geography) barriers to accessing care. Addressing these barriers through the provision of alternative treatment delivery models is imperative, particularly as effective and earlier intervention is likely to reduce the need for more costly and intensive treatment resulting from escalating methamphetamine use. In this project, the investigators will conduct the first double-blind, parallel-group, randomised controlled trial (RCT) examining the effectiveness of the structured telephone-delivered intervention, Ready2Change (R2C), among participants with methamphetamine use problems (R2C-M). Cost effectiveness of R2C-M will also be investigated. Factors influencing program implementation will be evaluated to inform the scalability of this intervention for practice nationally, and for replication internationally.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04713124
Study type Interventional
Source Turning Point
Contact
Status Completed
Phase N/A
Start date February 4, 2021
Completion date January 25, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT04178993 - Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine] Phase 1
Completed NCT01982643 - Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder Phase 1/Phase 2
Completed NCT03078075 - Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder Phase 3
Terminated NCT05711862 - The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder Phase 2
Recruiting NCT05322954 - Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder Phase 1
Recruiting NCT05760807 - Intranasal Oxytocin for Methamphetamine Withdrawal in Women N/A
Recruiting NCT04614584 - Mirtazapine and Methamphetamine Drug-drug Interaction Study Phase 1
Not yet recruiting NCT06320366 - Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder N/A
Recruiting NCT05558358 - Deep Brain Stimulation (DBS) for Methamphetamine Use Disorder Phase 1/Phase 2
Active, not recruiting NCT06279273 - A Study for the Risky Decision-making Deficits Among Methamphetamine Dependence Individuals and Treatment N/A
Active, not recruiting NCT04907357 - rTMS for Stimulant Use Disorders N/A
Active, not recruiting NCT04791969 - Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM Phase 2
Completed NCT00572234 - Bupropion in the Treatment of Methamphetamine Dependence N/A
Terminated NCT03106571 - Study of Pomaglumetad and Methamphetamine Phase 1
Recruiting NCT06033365 - Beginning Early and Assertive Treatment for Methamphetamine Use Disorder N/A